Alta Partners Promotes Alison de Bord to Director.Adam Tomasi, Ph.D Joins as Kauffman Fellow SAN FRANCISCO San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden -- Alta Partners, a life sciences venture capital firm based in San Francisco, today announced that Alison de Bord has been promoted to Director. Alison joins Alta's other six Directors responsible for investing Alta Partners VIII. She currently represents Alta as a Director on the boards of Aegerion Pharmaceuticals, Insulet and SurgRx, and was directly involved in Alta's investments in Esperion Therapeutics and Kerberos Proximal Solutions. "Over the past 5 years, Alison has proven to be a valued member of the Alta team. Building upon her life sciences banking and research experience, Alison has honed her investment skills here at Alta and developed terrific instincts," said Guy Nohra, Managing Director at Alta Partners. "We are confident that Alison will continue to find promising investments for Alta, provide informed leadership for our companies and help the firm deliver strong returns for our investors." Alison was a Principal in Alta BioPharma III most recently, and joined Alta Partners as an Associate in 2001. Prior to Alta, Alison was a Senior Associate in Robertson Stephens' Life Sciences Investment Banking Group with primary responsibilities for the execution of corporate finance transactions including IPOs, follow-on equity and convertible preferred offerings. Previously, she was an Associate in Robertson Stephens' equity research group where she focused on growth medical technology companies. She began her career in the business development group at Geron, a biotechnology company. Alison earned a Master of Business Administration from Columbia Business School Columbia Business School (part of Columbia University), officially named the Columbia University Graduate School of Business, and also known as CBS, was established in 1916 to provide business training and professional preparation for undergraduate and graduate and a Bachelor of Arts in History from Colgate University Colgate University Private university in Hamilton, N.Y. It was founded in 1819 as a Baptist-affiliated institution but became independent in 1928. It offers primarily a liberal arts curriculum for undergraduates, with some master's degree programs in arts and teaching. . In addition, Adam Tomasi, Ph.D. has joined the firm as a Kauffman fellow. Prior to joining Alta, Adam was a student in the Harvard-MIT Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Enterprise Program and held lead scientific positions in medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. at Cytokinetics and Gilead Sciences. Adam completed his Ph.D. at UC Irvine where he was a Fellow of the American Chemical Society The American Chemical Society (ACS) is a learned society (professional association) based in the United States that supports scientific inquiry in the field of chemistry. Founded in 1876 at New York University, the ACS currently has over 160,000 members at all degree-levels and in and the UC Regents. He continued his education with a postdoctoral role at The Scripps Research Institute/The Genomics Institute of the Novartis Foundation. Adam holds a B.S. in Chemistry from UC Berkeley, a Ph.D. in Chemistry from UC Irvine, and an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from MIT MIT - Massachusetts Institute of Technology Sloan. About Alta Partners Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 110 companies in the sector to date. www.altapartners.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion